Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: BioNTech SE

Market Cap 19.93B 22.69B 18.36B 17.19B 32.21B 2,149B 32.75B 220B 85.35B 1,054B 85.16B 83.33B 3,665B P/E 2026 *
-17.9x
P/E 2027 * -17.6x
Enterprise Value 9.08B 10.33B 8.36B 7.83B 14.67B 979B 14.92B 100B 38.88B 480B 38.79B 37.95B 1,669B EV / Sales 2026 *
4.19x
EV / Sales 2027 * 4.77x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 2017-12-31
Chief Executive Officer 60 2008-06-01
Director of Finance/CFO - 2025-06-30
Director TitleAgeSince
Chairman 55 2008-06-01
Director/Board Member 69 2008-06-01
Director/Board Member 65 2017-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-20.75%+2.41% - - 22.81B
+2.14%+7.57%+74.46%+123.84% 56.65B
-0.49%+6.98%+62.88%+67.95% 47.49B
+3.14%+7.15%-2.91%+412.78% 21.37B
+1.30%+0.71%+29.21%-17.51% 16.12B
+3.20%+9.80%+26.27%-34.74% 15.56B
+0.52%-0.98%+18.95%+159.77% 12.91B
0.00%+15.02%+133.24%+273.89% 12.86B
+1.43%-5.06%+23.53% - 11.67B
+0.81%+3.11%+82.62%+117.44% 11.82B
Average +1.44%+2.55%+49.81%+137.93% 22.94B
Weighted average by Cap. +1.40%+3.80%+54.40%+129.45%

Financials

2026 *2027 *
Net sales 2.17B 2.47B 2B 1.87B 3.5B 234B 3.56B 23.96B 9.28B 115B 9.26B 9.06B 398B 2.23B 2.54B 2.06B 1.92B 3.6B 241B 3.67B 24.68B 9.55B 118B 9.53B 9.33B 410B
Net income -1.05B -1.2B -968M -906M -1.7B -113B -1.73B -11.63B -4.5B -55.6B -4.49B -4.39B -193B -1.17B -1.33B -1.07B -1.01B -1.88B -126B -1.92B -12.89B -4.99B -61.66B -4.98B -4.87B -214B
Net Debt -10.85B -12.35B -10B -9.36B -17.54B -1,170B -17.83B -120B -46.48B -574B -46.37B -45.38B -1,996B -9.28B -10.56B -8.55B -8.01B -15B -1,001B -15.25B -103B -39.75B -491B -39.66B -38.8B -1,707B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
-
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!